441 related articles for article (PubMed ID: 26678637)
1. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Aulin J; Siegbahn A; Hijazi Z; Ezekowitz MD; Andersson U; Connolly SJ; Huber K; Reilly PA; Wallentin L; Oldgren J
Am Heart J; 2015 Dec; 170(6):1151-60. PubMed ID: 26678637
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
[TBL] [Abstract][Full Text] [Related]
5. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
6. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
[TBL] [Abstract][Full Text] [Related]
7. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
[TBL] [Abstract][Full Text] [Related]
9. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA
Roldán V; Rivera-Caravaca JM; Shantsila A; García-Fernández A; Esteve-Pastor MA; Vilchez JA; Romera M; Valdés M; Vicente V; Marín F; Lip GYH
Ann Med; 2018 Feb; 50(1):26-34. PubMed ID: 28892413
[TBL] [Abstract][Full Text] [Related]
12. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
[TBL] [Abstract][Full Text] [Related]
13. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation.
Conway DS; Buggins P; Hughes E; Lip GY
Am Heart J; 2004 Sep; 148(3):462-6. PubMed ID: 15389233
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L; Rosenqvist M; Lip GY
Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
[TBL] [Abstract][Full Text] [Related]
16. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
17. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.
Sharma A; Hijazi Z; Andersson U; Al-Khatib SM; Lopes RD; Alexander JH; Held C; Hylek EM; Leonardi S; Hanna M; Ezekowitz JA; Siegbahn A; Granger CB; Wallentin L
Circulation; 2018 Oct; 138(16):1666-1676. PubMed ID: 29871978
[TBL] [Abstract][Full Text] [Related]
18. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
[TBL] [Abstract][Full Text] [Related]
19. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
Skoglund PH; Arpegård J; Ostergren J; Svensson P
Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
[TBL] [Abstract][Full Text] [Related]
20. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.
Douketis JD; Healey JS; Brueckmann M; Eikelboom JW; Ezekowitz MD; Fraessdorf M; Noack H; Oldgren J; Reilly P; Spyropoulos AC; Wallentin L; Connolly SJ
Thromb Haemost; 2015 Mar; 113(3):625-32. PubMed ID: 25472710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
